Lessons from the avandia controversy: A new paradigm for the development of drugs to treat type 2 diabetes

Diabetes Care

Volumn 30, Issue 12, 2007, Pages 3141-3144

  Misbin, Robert I ^a,b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; MURAGLITAZAR; PHENFORMIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; TROGLITAZONE;

CARDIOTOXICITY; DRUG APPROVAL; DRUG MARKETING; DRUG SAFETY; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG APPROVAL; HUMANS; HYPOGLYCEMIC AGENTS; META-ANALYSIS AS TOPIC; THIAZOLIDINEDIONES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 37149010268     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-1908     Document Type: Note

References (26)

1. Misbin RI: Phenformin associated lactic acidosis: pathogenisis and treatment. Ann Intern Med 87:591-595, 1977
2. Misbin RI: The phantom of lactic acidosis due to metformin in patients with type 2 diabetes. Diabetes Care 27:1791-1793, 2004
3. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
4. Golden J: Muraglitazar safety analysis. Presented at the Food and Drug Administration Metabolic and Endocrine Advisory Committee Meeting, 9 September 2005, Silver Spring, Maryland
5. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2467-2471, 2007
6. Psaty BM, Furberg CD: Rosiglitazone and cardiovascular risk. N Engl J Med 356:2522-2524, 2007
7. Bloomgarden ZT: The Avandia debate. Diabetes Care 30:2401-2410, 2007
8. Nathan DM: Finding new treatments of diabetes: how many, how fast. . . how good? N Engl J Med 356:437-440, 2007
9. Misbin RI: A possible drug fix? Washington Post, 24 Aug 1998: Sect. A, p. 18
10. Misbin RI: Evaluating the safety of diabetes drugs: perspective of a Food and Drug Administration insider. Diabetes Care 28:2573-2576, 2005
11. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risks of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
12. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with metformin complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
13. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA 290:486-494, 2003
14. Hanefield M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M: Acarbose reduces the risk of myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25:10-16, 2004
15. Psaty BM, Weiss NS, Furburg CSD, Koepsell TD, Siscovick DS, Rosendaal FR, Smith NL, Heckbert SR, Kaplan RC, Lin D, Fleming TR, Wagner EH: Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 282:786-790, 1999
16. Psaty BM, Furberg CD: Rosiglitazone and the FDA. N Engl J Med. 29 August 2007 [Epub] (DOI: 10.1056/NEJMc076347)
17. Nathan DM: Rosiglitazone and cardiotoxicity: weighing the evidence. N Engl J Med 357:64-66, 2007
18. Skyler JS: PROactive: a sad tale of inappropriate analysis and unjustified interpretation. Clinical Diabetes 24:63-64, 2006
19. Fonseca V, Jawa A, Asnani S: Commentary: the PROactive Study: the glass is half full. J Clin Endocrinol Metab 91:25-27, 2006
20. Food and Drug Administration: Medical Officers Review of Avandia. Rockville, MD, Food and Drug Administration, 1999 (application no. 021071)
21. Committee on Oversight and Government Reform: Hearing on FDA's Role in Evaluating Safety of Avandia [article online], 2007. Available from http://oversight.house.gov/story.asp?ID=1325. Accessed 6 June 2007
22. Misbin RI: Troglitazone: associated hepatic failure. Ann Intern Med 130:330, 1999
23. Kahn SE, Haffner SM, Heise MA Herman WH, Holman RR, Jones NP, Kravatz BG, Lachman JM, O'Neill MC, Zinman B, Viberti G: Glycemic durability of rosiglitazone, metformin or glyburide monotherapy. N Engl J Med 355:2427-2443, 2006
24. Food and Drug Administration: Medical Officers Review of Actos. Rockville, MD, Food and Drug Administration, 2007 (application no. 021073)
25. American Diabetes Association: Standards of medical care in diabetes - 2007 (Position Statement). Diabetes Care 30 (Suppl. 1):S4-S41, 2007
26. Scranton RE, Gaziano JM, Rutty D, Cincotta MA: A randomized, double-blind, placebo-controlled trial of safety and tolerability during treatment of type 2 diabetes with either Cycloset or placebo. BMC Endocr Disord 7:3, 2007